Novel CAR T Cells Targeting Cathepsin G Signal Peptide Show Promise in Leukemia Treatment
Published: May 16, 2026 | Source: Leukemia (2025) | Category: cathepsin G signal peptide, CG1
Overview
A recent study published in Leukemia reveals the potential of chimeric antigen receptor (CAR) T cells targeting a specific signal peptide derived from cathepsin G (CG), known as CG1. This research offers new hope for treating acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) by leveraging an innovative immunotherapy approach.
Study Background
Immunotherapies have revolutionized cancer treatment, but the development of effective targets in myeloid malignancies has been challenging. The study builds on previous research where a T cell receptor mimic antibody targeting CG1 was developed and shown to be safe and efficacious against AML and CML. This new work aims to extend these findings by engineering CAR T cells that can recognize and target the same HLA-A2-restricted signal peptide, CG1.
What the Research Found
Researchers engineered CAR T cells using a T cell receptor mimic (TCR-m) specific for CG1/A2 complexes. These modified CAR T cells demonstrated high affinity for both CG1/A2 monomers and leukemia cells expressing this complex. The study showed that these CAR T cells were effective in preclinical models of AML and CML, indicating their potential as a therapeutic tool against these diseases.
What This Means for Peptide Users
While the findings are promising, it is important to note that this research has only been conducted in preclinical settings. For peptide users, particularly those involved in immunotherapy development or clinical trials, the study highlights a new direction in targeting myeloid malignancies through specific signal peptides. However, further validation and clinical testing are necessary before these CAR T cells can be used in patient care.
Limitations and Caveats
The primary limitation of this research is its preclinical nature; no human subjects have been involved yet. Additionally, the study focuses on HLA-A2-restricted CG1/A2 complexes, which limits applicability to patients with this specific genetic marker. The safety and efficacy profiles in humans remain unknown until clinical trials are conducted.
How This Compares to Previous Research
This work builds upon earlier studies that established the feasibility of targeting CG1 using TCR-m antibodies. Unlike those previous efforts, however, this study introduces a novel approach by utilizing CAR T cells engineered with the same specificity. While both methods show promise in preclinical settings, the use of CAR T cells may offer advantages such as enhanced persistence and anti-tumor activity.
Our Analysis
PeptideVault views this research positively but emphasizes the need for caution due to its preliminary stage. The innovative approach of targeting a signal peptide with CAR T cells represents an exciting development in cancer immunotherapy, particularly for myeloid malignancies where effective targets have been scarce. However, rigorous clinical validation is essential before these findings can be translated into practical medical applications.
Key Takeaways
- Novel Target: CG1/A2 complexes represent a promising new target for CAR T cell therapy.
- Preclinical Success: The study demonstrates efficacy in preclinical models of AML and CML.
- Clinical Validation Needed: Further research is required to confirm safety and effectiveness in human patients.
Original Source
Citation: Yan Jun, Shi Chunhua, Yang Guojun et al. (2025). T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.. Leukemia. DOI: 10.1038/s41375-025-02652-0
Access: https://pubmed.ncbi.nlm.nih.gov/40437170/
---
This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.